Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis

Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-04, Vol.10 (4), p.e0124230-e0124230
Main Authors: Zhu, Lin, Yu, Hong, Liu, Shi-Yuan, Xiao, Xiang-Sheng, Dong, Wei-Hua, Chen, Yi-Nan, Xu, Wei, Zhu, Tong
Format: Article
Language:English
Subjects:
Analysis
Biomarkers, Tumor - metabolism
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - enzymology
Care and treatment
Confidence intervals
Female
Glycoproteins
Heterogeneity
Hospitals
Humans
Immunohistochemistry
Inhibitors
Lung cancer
Lung carcinoma
Lung diseases
Lung Neoplasms - enzymology
Male
Matrix metalloproteinase
Medical ethics
Medical imaging
Medical prognosis
Medical research
Meta-analysis
Metalloproteinase
Metastasis
Middle Aged
Mutation
Non-small cell lung cancer
Non-small cell lung carcinoma
Patients
Prognosis
Proteins
Small cell lung cancer
Small cell lung carcinoma
Subgroups
Survival
Systematic review
Test procedures
Tissue inhibitor of metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2 - metabolism
Tissues
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043
cites cdi_FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043
container_end_page e0124230
container_issue 4
container_start_page e0124230
container_title PloS one
container_volume 10
creator Zhu, Lin
Yu, Hong
Liu, Shi-Yuan
Xiao, Xiang-Sheng
Dong, Wei-Hua
Chen, Yi-Nan
Xu, Wei
Zhu, Tong
description Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (
doi_str_mv 10.1371/journal.pone.0124230
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1675171904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A422547870</galeid><doaj_id>oai_doaj_org_article_0ad8d81d9dac4d94a96d87ae87366f66</doaj_id><sourcerecordid>A422547870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043</originalsourceid><addsrcrecordid>eNqNk9tq3DAQhk1padK0b1BaQ6G0F95KtizZvSiE0EMgkNLTrRjL410FW3IleZN9lL5t5ewmZEsuikEW42_-OXgmSZ5TsqCFoO8u7OQM9IvRGlwQmrO8IA-SQ1oXecZzUjy8cz9Innh_QUhZVJw_Tg7ysialqMRh8uers0tjfdAqXUM_YWq7NGjv402blW50sG62DRig7-3obEBtwGOWp3g1OvReWxPZdISg0QSfXuqwSo01mR-iS6owHv1klqkCo9C9TyH1Gx9wgDmqw7XGyxRMex0jg1jUxmv_NHnUQe_x2e59lPz89PHHyZfs7Pzz6cnxWaZ4nYcMhVBl3nSiKZlqKwFd05YNY1C3UNUdAcYV6RosueKCVA0tGihrSkgNNCeEFUfJy63u2Fsvd131knJRUkHra-J0S7QWLuTo9ABuIy1oeW2wbinBxVJ6lATaqq1oG4Mr1tYxCz7nhJUoOO84j1ofdtGmZsBWxYY56PdE978YvZJLu5aMkYqUZRR4sxNw9veEPshB-7nFYNBO27wrwWpRRfTVP-j91e2oJcQCtOlsjKtmUXnM8rxkcU5IpBb3UPFpcdAqjmCno33P4e2eQ2QCXoUlTN7L0-_f_p89_7XPvr7DrhD6sPK2n0KcQr8Psi2onPXeYXfbZErkvEE33ZDzBsndBkW3F3d_0K3TzcoUfwEbHhmh</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675171904</pqid></control><display><type>article</type><title>Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Zhu, Lin ; Yu, Hong ; Liu, Shi-Yuan ; Xiao, Xiang-Sheng ; Dong, Wei-Hua ; Chen, Yi-Nan ; Xu, Wei ; Zhu, Tong</creator><contributor>Rosell, Rafael</contributor><creatorcontrib>Zhu, Lin ; Yu, Hong ; Liu, Shi-Yuan ; Xiao, Xiang-Sheng ; Dong, Wei-Hua ; Chen, Yi-Nan ; Xu, Wei ; Zhu, Tong ; Rosell, Rafael</creatorcontrib><description>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (&lt;50%) were 0.63 (95% CI: 0.43-0.92), 0.55 (95% CI: 0.41-0.74), and 0.50 (95% CI: 0.28-0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias. TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0124230</identifier><identifier>PMID: 25905787</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Biomarkers, Tumor - metabolism ; Cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - enzymology ; Care and treatment ; Confidence intervals ; Female ; Glycoproteins ; Heterogeneity ; Hospitals ; Humans ; Immunohistochemistry ; Inhibitors ; Lung cancer ; Lung carcinoma ; Lung diseases ; Lung Neoplasms - enzymology ; Male ; Matrix metalloproteinase ; Medical ethics ; Medical imaging ; Medical prognosis ; Medical research ; Meta-analysis ; Metalloproteinase ; Metastasis ; Middle Aged ; Mutation ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Patients ; Prognosis ; Proteins ; Small cell lung cancer ; Small cell lung carcinoma ; Subgroups ; Survival ; Systematic review ; Test procedures ; Tissue inhibitor of metalloproteinase 2 ; Tissue Inhibitor of Metalloproteinase-2 - metabolism ; Tissues</subject><ispartof>PloS one, 2015-04, Vol.10 (4), p.e0124230-e0124230</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Zhu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Zhu et al 2015 Zhu et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043</citedby><cites>FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1675171904/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1675171904?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,730,783,787,888,25767,27938,27939,37026,37027,44604,53806,53808,75462</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25905787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Rosell, Rafael</contributor><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Yu, Hong</creatorcontrib><creatorcontrib>Liu, Shi-Yuan</creatorcontrib><creatorcontrib>Xiao, Xiang-Sheng</creatorcontrib><creatorcontrib>Dong, Wei-Hua</creatorcontrib><creatorcontrib>Chen, Yi-Nan</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Zhu, Tong</creatorcontrib><title>Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (&lt;50%) were 0.63 (95% CI: 0.43-0.92), 0.55 (95% CI: 0.41-0.74), and 0.50 (95% CI: 0.28-0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias. TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future.</description><subject>Analysis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - enzymology</subject><subject>Care and treatment</subject><subject>Confidence intervals</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Heterogeneity</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Inhibitors</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - enzymology</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Medical ethics</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Metalloproteinase</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Small cell lung cancer</subject><subject>Small cell lung carcinoma</subject><subject>Subgroups</subject><subject>Survival</subject><subject>Systematic review</subject><subject>Test procedures</subject><subject>Tissue inhibitor of metalloproteinase 2</subject><subject>Tissue Inhibitor of Metalloproteinase-2 - metabolism</subject><subject>Tissues</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tq3DAQhk1padK0b1BaQ6G0F95KtizZvSiE0EMgkNLTrRjL410FW3IleZN9lL5t5ewmZEsuikEW42_-OXgmSZ5TsqCFoO8u7OQM9IvRGlwQmrO8IA-SQ1oXecZzUjy8cz9Innh_QUhZVJw_Tg7ysialqMRh8uers0tjfdAqXUM_YWq7NGjv402blW50sG62DRig7-3obEBtwGOWp3g1OvReWxPZdISg0QSfXuqwSo01mR-iS6owHv1klqkCo9C9TyH1Gx9wgDmqw7XGyxRMex0jg1jUxmv_NHnUQe_x2e59lPz89PHHyZfs7Pzz6cnxWaZ4nYcMhVBl3nSiKZlqKwFd05YNY1C3UNUdAcYV6RosueKCVA0tGihrSkgNNCeEFUfJy63u2Fsvd131knJRUkHra-J0S7QWLuTo9ABuIy1oeW2wbinBxVJ6lATaqq1oG4Mr1tYxCz7nhJUoOO84j1ofdtGmZsBWxYY56PdE978YvZJLu5aMkYqUZRR4sxNw9veEPshB-7nFYNBO27wrwWpRRfTVP-j91e2oJcQCtOlsjKtmUXnM8rxkcU5IpBb3UPFpcdAqjmCno33P4e2eQ2QCXoUlTN7L0-_f_p89_7XPvr7DrhD6sPK2n0KcQr8Psi2onPXeYXfbZErkvEE33ZDzBsndBkW3F3d_0K3TzcoUfwEbHhmh</recordid><startdate>20150423</startdate><enddate>20150423</enddate><creator>Zhu, Lin</creator><creator>Yu, Hong</creator><creator>Liu, Shi-Yuan</creator><creator>Xiao, Xiang-Sheng</creator><creator>Dong, Wei-Hua</creator><creator>Chen, Yi-Nan</creator><creator>Xu, Wei</creator><creator>Zhu, Tong</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150423</creationdate><title>Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis</title><author>Zhu, Lin ; Yu, Hong ; Liu, Shi-Yuan ; Xiao, Xiang-Sheng ; Dong, Wei-Hua ; Chen, Yi-Nan ; Xu, Wei ; Zhu, Tong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - enzymology</topic><topic>Care and treatment</topic><topic>Confidence intervals</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Heterogeneity</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Inhibitors</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - enzymology</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Medical ethics</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Metalloproteinase</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Small cell lung cancer</topic><topic>Small cell lung carcinoma</topic><topic>Subgroups</topic><topic>Survival</topic><topic>Systematic review</topic><topic>Test procedures</topic><topic>Tissue inhibitor of metalloproteinase 2</topic><topic>Tissue Inhibitor of Metalloproteinase-2 - metabolism</topic><topic>Tissues</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Yu, Hong</creatorcontrib><creatorcontrib>Liu, Shi-Yuan</creatorcontrib><creatorcontrib>Xiao, Xiang-Sheng</creatorcontrib><creatorcontrib>Dong, Wei-Hua</creatorcontrib><creatorcontrib>Chen, Yi-Nan</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><creatorcontrib>Zhu, Tong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Science (Gale in Context)</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Database (Proquest)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Lin</au><au>Yu, Hong</au><au>Liu, Shi-Yuan</au><au>Xiao, Xiang-Sheng</au><au>Dong, Wei-Hua</au><au>Chen, Yi-Nan</au><au>Xu, Wei</au><au>Zhu, Tong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-04-23</date><risdate>2015</risdate><volume>10</volume><issue>4</issue><spage>e0124230</spage><epage>e0124230</epage><pages>e0124230-e0124230</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-Review-4</notes><notes>content type line 23</notes><notes>ObjectType-Undefined-3</notes><notes>Conceived and designed the experiments: HY LZ SYL XSX. Performed the experiments: HY LZ TZ YNC. Analyzed the data: LZ SYL WHD WX. Contributed reagents/materials/analysis tools: TZ YNC WHD WX XSX. Wrote the paper: LZ HY YNC TZ.</notes><notes>Competing Interests: The authors have the following interests: co-author Tong Zhu is employed by Shanghai United Imaging Healthcare Co., Ltd. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</notes><abstract>Tissue inhibitor of metalloproteinase-2 (TIMP-2) is a small secretory glycoprotein with anti-matrix metalloproteinase activity. Data on the value of TIMP-2 as a prognostic factor in non-small cell lung cancer (NSCLC) are discordant and remain controversial. A systematic review and meta-analysis was performed to explore this issue. We identified the relevant literature by searching the PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang Data databases (search terms: "non-small cell lung cancer" or "NSCLC" or "Lung Carcinoma, Non-Small-Cell", "Tissue Inhibitor of Metalloproteinase-2" or "TIMP-2", and "prognosis" or "prognostic" or "survive") for updates prior to March 1, 2014. The pooled hazard ratio (HR) of overall survival with a 95% confidence interval (95% CI) was used to evaluate the strength of the association between positive TIMP-2 expression and survival in patients with NSCLC. We included 12 studies in our systematic review; five studies involving 399 patients with NSCLC were meta-analyzed. The pooled HR of all included patients was 0.57 (95% CI: 0.43-0.77), and the HRs of subgroup analysis according to stage (I-IV), testing method (immunohistochemistry) and high TIMP-2 expression percentage (&lt;50%) were 0.63 (95% CI: 0.43-0.92), 0.55 (95% CI: 0.41-0.74), and 0.50 (95% CI: 0.28-0.88), respectively. These data suggested that high TIMP-2 expression is associated with favorable prognosis in NSCLC. The meta-analysis did not reveal heterogeneity or publication bias. TIMP-2 expression indicates favorable prognosis in patients with NSCLC; as a protective factor, it could help predict outcome and may guide clinical therapy in the future.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25905787</pmid><doi>10.1371/journal.pone.0124230</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2015-04, Vol.10 (4), p.e0124230-e0124230
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1675171904
source Publicly Available Content Database; PubMed Central
subjects Analysis
Biomarkers, Tumor - metabolism
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - enzymology
Care and treatment
Confidence intervals
Female
Glycoproteins
Heterogeneity
Hospitals
Humans
Immunohistochemistry
Inhibitors
Lung cancer
Lung carcinoma
Lung diseases
Lung Neoplasms - enzymology
Male
Matrix metalloproteinase
Medical ethics
Medical imaging
Medical prognosis
Medical research
Meta-analysis
Metalloproteinase
Metastasis
Middle Aged
Mutation
Non-small cell lung cancer
Non-small cell lung carcinoma
Patients
Prognosis
Proteins
Small cell lung cancer
Small cell lung carcinoma
Subgroups
Survival
Systematic review
Test procedures
Tissue inhibitor of metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2 - metabolism
Tissues
title Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-05T18%3A52%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20tissue%20inhibitor%20of%20metalloproteinase-2%20expression%20in%20patients%20with%20non-small%20cell%20lung%20cancer:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=PloS%20one&rft.au=Zhu,%20Lin&rft.date=2015-04-23&rft.volume=10&rft.issue=4&rft.spage=e0124230&rft.epage=e0124230&rft.pages=e0124230-e0124230&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0124230&rft_dat=%3Cgale_plos_%3EA422547870%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-e77c52bf7b54cd87afbd5b44a9da89f0a46c0fbe56c6708b13ba591009a120043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1675171904&rft_id=info:pmid/25905787&rft_galeid=A422547870&rfr_iscdi=true